Cargando…

Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods

INTRODUCTION: Advanced gastric cancer (AGC) is one of the most common forms of cancer and remains difficult to cure. There is currently no recommended therapy for second-line AGC in the UK despite the availability of various interventions. This paper aims to compare different interventions for treat...

Descripción completa

Detalles Bibliográficos
Autor principal:	Harvey, Rebecca C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488131/ https://www.ncbi.nlm.nih.gov/pubmed/28680955 http://dx.doi.org/10.1007/s40487-017-0048-0

Ejemplares similares

Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
por: Salati, Massimiliano, et al.
Publicado: (2017)

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
por: Amzal, Billy, et al.
Publicado: (2017)

Overall Survival Prediction of Docetaxel-based Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
por: Nagaraju, Chaitra, et al.
Publicado: (2022)

Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
por: Whitaker, Kristen D., et al.
Publicado: (2022)

Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data
por: Qi, Wei-Xiang, et al.
Publicado: (2013)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
por: Amdahl, Jordan, et al.
Publicado: (2016)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Digital spectral analysis: parametric, non-parametric and advanced methods
por: Castanié, Francis
Publicado: (2013)

Phase II study of sunitinib as second-line treatment for advanced gastric cancer
por: Bang, Yung-Jue, et al.
Publicado: (2010)

Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer
por: Shimokawa, Mototsugu, et al.
Publicado: (2018)

Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
por: Solimando, Antonio Giovanni, et al.
Publicado: (2021)

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
por: Cotes Sanchís, Almudena, et al.
Publicado: (2020)

Advances in sensitivity analysis and parametric programming
por: Gal, Tomas, et al.
Publicado: (1997)

Multi-Parametric Deep Learning Model for Prediction of Overall Survival after Postoperative Concurrent Chemoradiotherapy in Glioblastoma Patients
por: Yoon, Han Gyul, et al.
Publicado: (2020)

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
por: Iacovelli, Roberto, et al.
Publicado: (2014)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
por: Chan, Sik-Kwan, et al.
Publicado: (2022)

Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials
por: Zhang, Yong, et al.
Publicado: (2016)

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
por: Fuchs, Charles S., et al.
Publicado: (2017)

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
por: Huang, Lihong, et al.
Publicado: (2016)

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
por: Rothschild, S.I., et al.
Publicado: (2021)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
por: Ji, Sang Hoon, et al.
Publicado: (2009)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
por: Yang, Liuting, et al.
Publicado: (2018)

Efficacy of Acupuncture and Moxibustion as a Subsequent Treatment after Second-Line Chemotherapy in Advanced Gastric Cancer
por: Zhang, Yong-jie, et al.
Publicado: (2020)

Helios Expression in Tumor-Infiltrating Lymphocytes Correlates with Overall Survival of Advanced Gastric Cancer Patients
por: Chen, Wei-Ming, et al.
Publicado: (2020)

CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy
por: Tong, Yilin, et al.
Publicado: (2021)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
por: Petersohn, Svenja, et al.
Publicado: (2023)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
por: Swallow, Elyse, et al.
Publicado: (2018)

Overall survival and second primary malignancies in men with metastatic prostate cancer
por: Mehtälä, Juha, et al.
Publicado: (2020)

Types of second primary cancer influence overall survival in cutaneous melanoma
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Efficacy and safety of paclitaxel with or without targeted therapy as second-line therapy in advanced gastric cancer: A meta-analysis
por: Zheng, Ting, et al.
Publicado: (2020)

Neural Survival Clustering: Non-parametric mixture of neural networks for survival clustering
por: Jeanselme, Vincent, et al.
Publicado: (2022)

CGB5 expression is independently associated with poor overall survival and recurrence‐free survival in patients with advanced gastric cancer
por: Yang, Yuxin, et al.
Publicado: (2018)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jfasdhj7gdhbo9ar7q2shps3na